Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 3
2005 2
2007 1
2008 1
2010 1
2012 2
2014 1
2015 3
2016 3
2017 1
2018 3
2019 6
2020 6
2021 10
2022 6
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C, Finneran L, Roe J, Sydenham MA, Beasley M, Bhide S, Boon C, Cook A, De Winton E, Emson M, Foran B, Frogley R, Petkar I, Pettit L, Rooney K, Roques T, Srinivasan D, Tyler J, Hall E; DARS Trialist Group. Nutting C, et al. Among authors: beasley m. Lancet Oncol. 2023 Aug;24(8):868-880. doi: 10.1016/S1470-2045(23)00265-6. Epub 2023 Jul 6. Lancet Oncol. 2023. PMID: 37423227 Free article. Clinical Trial.
Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansion.
Sun Y, Florio TJ, Gupta S, Young MC, Marshall QF, Garfinkle SE, Papadaki GF, Truong HV, Mycek E, Li P, Farrel A, Church NL, Jabar S, Beasley MD, Kiefel BR, Yarmarkovich M, Mallik L, Maris JM, Sgourakis NG. Sun Y, et al. Among authors: beasley md. bioRxiv [Preprint]. 2023 May 24:2023.05.24.542108. doi: 10.1101/2023.05.24.542108. bioRxiv. 2023. PMID: 37292750 Free PMC article. Updated. Preprint.
Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion.
Sun Y, Florio TJ, Gupta S, Young MC, Marshall QF, Garfinkle SE, Papadaki GF, Truong HV, Mycek E, Li P, Farrel A, Church NL, Jabar S, Beasley MD, Kiefel BR, Yarmarkovich M, Mallik L, Maris JM, Sgourakis NG. Sun Y, et al. Among authors: beasley md. Sci Immunol. 2023 Dec;8(90):eadj5792. doi: 10.1126/sciimmunol.adj5792. Epub 2023 Dec 1. Sci Immunol. 2023. PMID: 38039376 Free PMC article.
The maturation of antibody technology for the HIV epidemic.
Winnall WR, Beasley MD, Center RJ, Parsons MS, Kiefel BR, Kent SJ. Winnall WR, et al. Among authors: beasley md. Immunol Cell Biol. 2014 Aug;92(7):570-7. doi: 10.1038/icb.2014.35. Epub 2014 May 6. Immunol Cell Biol. 2014. PMID: 24797582 Review.
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
Wadsley J, Ainsworth G, Coulson AB, Garcez K, Moss L, Newbold K, Farnell K, Swain J, Howard H, Beasley M, Weaver A, Wood K, Marshall J, Griffin M, Pascoe A, Du Y, Taprogge J, Flux G, Brown S. Wadsley J, et al. Among authors: beasley m. Thyroid. 2023 Sep;33(9):1119-1123. doi: 10.1089/thy.2022.0707. Epub 2023 Sep 1. Thyroid. 2023. PMID: 37565288 Free PMC article. Clinical Trial. No abstract available.
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.
Marks DI, Castleton A, Olavarria E, Gilleece M, Fielding A, Mikhaeel G, Beasley M, Diez P, Jackson A, Hodgkinson A, Elhanied M, Chakraverty R. Marks DI, et al. Among authors: beasley m. BMJ Open. 2023 Jun 1;13(6):e067790. doi: 10.1136/bmjopen-2022-067790. BMJ Open. 2023. PMID: 37263700 Free PMC article.
49 results